XML 41 R31.htm IDEA: XBRL DOCUMENT v3.23.1
Description of Business and Basis of Presentation - Additional Information (Detail) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Nov. 30, 2020
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Place of incorporation   Arizona    
Year of incorporation   2002    
Place of reincorporation   Delaware    
Date of reincorporation   2015-03    
License revenue   $ 1,509,000 $ 3,220,000  
Net loss attributable to non-controlling interest   0 (122,000)  
Accumulated deficit   (267,243,000)   $ (257,859,000)
Cash and cash equivalents   22,998,000   20,644,000
Net loss   (9,384,000) (4,610,000) (15,600,000)
Net cash used in operations   (3,466,000) (4,885,000) (14,000,000.0)
Payment received on accounts and other receivable   285,000 $ 0  
Remaining accounts receivable and other receivables   $ 923,000   1,287,000
Reverse stock split   In February 2023, the Company’s board of directors approved a reverse split of 40:1 on the Company’s issued and outstanding common stock.    
Additional shares of common stock of reverse stock split   19,092    
Verdeca LLC [Member]        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Gain on sale of Verdeca       1,100,000
Bioceres Crop Solutions [Member]        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
License revenue       $ 862,000
Bioceres Crop Solutions [Member] | Verdeca LLC [Member]        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Additional cash receivable from sale of interest in joint venture $ 2,000,000.0      
Payment received on accounts and other receivable   $ 1,500,000    
Remaining accounts receivable and other receivables   $ 500,000    
Bioceres Crop Solutions [Member] | Verdeca LLC [Member] | Maximum [Member]        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Cash shares and royalty receivable $ 10,000,000.0